Stryker Corp. (SYK) VP Sells $1,368,360.00 in Stock
Stryker Corp. (NYSE:SYK) VP Yin C. Becker sold 12,000 shares of the stock in a transaction on Wednesday, October 12th. The shares were sold at an average price of $114.03, for a total value of $1,368,360.00. Following the sale, the vice president now owns 28,939 shares of the company’s stock, valued at approximately $3,299,914.17. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Shares of Stryker Corp. (NYSE:SYK) opened at 113.58 on Friday. The company has a market cap of $42.51 billion, a PE ratio of 26.78 and a beta of 0.72. The company has a 50 day moving average of $115.21 and a 200 day moving average of $114.05. Stryker Corp. has a 1-year low of $86.68 and a 1-year high of $123.55.
Stryker Corp. (NYSE:SYK) last issued its quarterly earnings data on Thursday, July 21st. The medical technology company reported $1.39 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.02. Stryker Corp. had a net margin of 15.33% and a return on equity of 23.61%. The business had revenue of $2.84 billion for the quarter, compared to analyst estimates of $2.79 billion. Equities analysts expect that Stryker Corp. will post $5.76 earnings per share for the current fiscal year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/14/stryker-corp-syk-vp-sells-1368360-00-in-stock.html
The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 31st. Investors of record on Friday, September 30th will be issued a dividend of $0.38 per share. The ex-dividend date of this dividend is Wednesday, September 28th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 1.34%. Stryker Corp.’s payout ratio is 35.85%.
Several large investors have recently modified their holdings of the company. Private Trust Co. NA raised its stake in shares of Stryker Corp. by 7.7% in the third quarter. Private Trust Co. NA now owns 20,232 shares of the medical technology company’s stock worth $2,355,000 after buying an additional 1,445 shares during the last quarter. Renaissance Investment Group LLC raised its stake in shares of Stryker Corp. by 8.2% in the third quarter. Renaissance Investment Group LLC now owns 2,970 shares of the medical technology company’s stock valued at $346,000 after buying an additional 225 shares during the last quarter. Cohen Capital Management Inc. raised its stake in shares of Stryker Corp. by 0.8% in the third quarter. Cohen Capital Management Inc. now owns 92,400 shares of the medical technology company’s stock valued at $10,756,000 after buying an additional 700 shares during the last quarter. Private Bank & Trust Co. raised its stake in shares of Stryker Corp. by 0.5% in the third quarter. Private Bank & Trust Co. now owns 4,222 shares of the medical technology company’s stock valued at $492,000 after buying an additional 23 shares during the last quarter. Finally, MSI Financial Services Inc raised its stake in shares of Stryker Corp. by 5.2% in the third quarter. MSI Financial Services Inc now owns 11,184 shares of the medical technology company’s stock valued at $1,302,000 after buying an additional 556 shares during the last quarter. Institutional investors and hedge funds own 75.49% of the company’s stock.
A number of equities research analysts have recently commented on the company. SunTrust Banks Inc. assumed coverage on Stryker Corp. in a research report on Thursday. They set a “buy” rating for the company. Zacks Investment Research downgraded Stryker Corp. from a “hold” rating to a “sell” rating in a research report on Tuesday, September 27th. Brean Capital reissued a “buy” rating and set a $125.00 target price (up from $121.00) on shares of Stryker Corp. in a research note on Monday, July 25th. Jefferies Group reissued a “hold” rating and set a $120.00 target price (up from $113.00) on shares of Stryker Corp. in a research note on Monday, July 25th. Finally, Canaccord Genuity reissued a “buy” rating and set a $130.00 target price on shares of Stryker Corp. in a research note on Sunday, July 24th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $114.91.
Stryker Corp. Company Profile
Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.
Receive News & Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related companies with MarketBeat.com's FREE daily email newsletter.